Specialty pharmaceutical company Zogenix, which recently launched Sumavel DosePro, a needle-free administration of migraine drug sumatriptan, filed on Friday with the SEC to raise up to $90 million in an initial public offering. The San Diego, CA-based company, which was founded in 2006 and booked $8 million in revenue for the 12 months ended June 30, plans to list on the NASDAQ under the symbol ZGNX. Zogenix had previously filed to go public in March 2008 before withdrawing the deal in August of the same year. Wells Fargo Securities and Leerink Swann are the lead underwriters on the deal, for which terms and timing were not disclosed.
